FDA approves first ever treatment for Rare Rapid-Aging Disease Progeria
Written By : Dr. Kamal Kant Kohli
Published On 2020-11-21 04:15 GMT | Update On 2020-11-21 07:55 GMT
The US Food and Drug Administration (FDA) has approved lonafarnib (Zokinvy) capsules for the for the treatment of Progeria and processing-deficient Progeroid Laminopathies (PL).
It has been approved for reducing risk of death from Hutchinson-Gilford progeria syndrome, as well as for the treatment of some processing-deficient progeroid laminopathies in patients 1 year and older.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd